- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
Spadin-Derived Peptide · Educational Resource
Understanding PE-22-28 and Neurogenesis Research
Spadin-Derived Analog
(Synthetic Peptide)
Investigational Application
Neurogenesis, mood research
Administration Protocol
Subcutaneous (subQ), per study protocol
Want to learn more?
A licensed team will reach out to guide you through the research.
Book a consultation →Spadin-Derived Peptide · Educational Resource
Understanding PE-22-28 and Neurogenesis Research
01 — Overview
What is PE-22-28?
PE-22-28 is a synthetic peptide analog derived from spadin, a peptide fragment of the sortilin propeptide, studied in early-stage preclinical literature for its relationship to mood and neurogenesis research.
As a very early-stage investigational compound, PE-22-28 has not received regulatory approval for therapeutic use in the Philippines or elsewhere, and existing literature is limited to laboratory and animal-model research.
Within research literature, PE-22-28 is most frequently studied for its relationship to TREK-1 channel modulation and hippocampal neurogenesis, areas summarized further below.
02 — How it works
How It Works: TREK-1 Channel Modulation and Neurogenic Signaling
As a spadin-derived analog, PE-22-28 is studied for its ability to inhibit TREK-1 potassium channels, a mechanism researchers associate with mood-related and antidepressant-like research effects in preclinical models.
Literature describes this channel-modulation mechanism as distinct from traditional monoamine-based approaches, positioning PE-22-28 within a novel research category focused on ion-channel-mediated mood research.
Administration in Research
In early-stage preclinical literature, PE-22-28 is evaluated primarily via subcutaneous injection within controlled laboratory research protocols. As a very early-stage investigational compound, it has not received regulatory approval for therapeutic use, and research contexts differ from any at-home or self-directed use.
03 — Areas of research
Summary of Investigated Research Areas
Early-stage preclinical literature evaluates PE-22-28 across several key physiological parameters to map its biological interactions:
TREK-1 Channel Signaling Pathways
Research literature evaluates how PE-22-28 is studied for its relationship to TREK-1 potassium channel inhibition, a pathway associated with mood-related research.
Neurogenesis Studies
Preclinical studies observe hippocampal neurogenesis markers following PE-22-28 exposure in animal research models.
Mood-Related Parameters
Investigational literature examines mood-related behavioral parameters in preclinical research models.
Stress Response Studies
Studies explore stress-response related measures associated with PE-22-28 administration in research settings.
Spadin Pathway Research
Some literature investigates PE-22-28's studied relationship to its parent compound spadin and TREK-1 channel-modulating pathways.
Pharmacokinetic Profiling
Studies characterize the absorption and elimination profile of PE-22-28 in preclinical research.
04 — FAQ
Frequently Asked Questions
Ano ba talaga ang PE-22-28?
Ang PE-22-28 ay isang synthetic peptide na hango mula sa spadin, isang peptide fragment ng sortilin propeptide. Pinag-aaralan ito sa early-stage research dahil sa posibleng papel nito sa mood at neurogenesis. Educational discussion lang ito, hindi sales o medical advice.
FDA-approved ba ito?
Hindi. Ang PE-22-28 ay very early-stage investigational compound na wala pang regulatory approval kahit saan. Karamihan ng literature ay laboratory at animal-model research pa lamang.
Paano ito naiiba sa traditional antidepressants?
Sa halip na tumarget sa monoamine pathways tulad ng traditional antidepressants, pinag-aaralan ang PE-22-28 dahil sa epekto nito sa TREK-1 potassium channels — ibang mekanismo ng research.
Pwede ba akong bumili nito dito?
Ang page na ito ay para sa educational purposes lamang. Hindi kami nagbebenta ng compounds dito online — kausapin ang isang lisensyadong healthcare provider para sa tamang gabay.
05 — References
References and Academic Literature
Moha ou Maati, H., et al. (2012). Spadin, a Sortilin-Derived Peptide, Targeting Rodent TREK-1 Channels: A New Concept for Antidepressant Drugs. Neuropharmacology.
Devader, C., et al. (2015). In Vivo Regulation of Neurogenesis and Neuronal Differentiation by TREK-1. Frontiers in Molecular Neuroscience.
Djillani, A., et al. (2017). Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology.
i
Medical Education Disclaimer: This page is intended strictly for educational and informational purposes regarding the scientific history and development of chemical compounds. It does not constitute medical advice, promotion, or advertising of any prescription medication. Any therapeutic applications must be evaluated and managed exclusively by a licensed medical practitioner.
Getting started
How to Get Started?
1. Consult
Book a free consultation with our licensed healthcare team.
100 % online. Hassle-free. Convenient.
2. Real Human Assessment
Talk with Philippine-licensed doctors and get prescribed.
Always doctor-led—never just an online form.
Free consultation with licensed providers
3. Start your Program
Your medication is prepared and delivered to your doorstep.
No lock-ins. No hidden fees. No subscriptions.
Formulated in FDA-regulated pharmacies
4. Consistent care
Stay on track with regular weekly follow-ups. On your chosen communication platform.
Unlimited complementary follow-ups